Based on these previous findings, we hypothesized that IL-17A may regulate the immune checkpoint molecule PDL1 and that inhibition of IL-17A may elicit an anti-tumor immune response in murine models of ER-negative breast cancer. The gene discussed is IL17A; the disease is neoplasm.